Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

Judgement, as one of the core tenets of medicine, relies upon the integration of multilayered
data with nuanced decision making. Cancer offers a unique context for medical decisions …

Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …

Cellular diversity in tumors is a key factor for therapeutic failures and lethal outcomes of solid
malignancies. Here, we determined the single-cell transcriptomic landscape of liver cancer …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

Intratumor heterogeneity (ITH) profoundly affects therapeutic responses and clinical
outcomes. However, the widespread methods for assessing ITH based on genomic …

Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for
hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the …